Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKA) is anticipated to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Oruka Therapeutics Stock Down 0.8%

Shares of ORKA stock opened at $35.28 on Thursday. The business has a 50-day moving average price of $32.08 and a two-hundred day moving average price of $25.95. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $36.53. The firm has a market cap of $1.71 billion, a P/E ratio of -18.57 and a beta of -0.38.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the transaction, the insider directly owned 34,018 shares of the company’s stock, valued at $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 21,000 shares of company stock valued at $663,530 over the last quarter. 24.69% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in ORKA. Millennium Management LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter worth about $1,780,000. Bank of America Corp DE increased its holdings in Oruka Therapeutics by 287.6% during the 2nd quarter. Bank of America Corp DE now owns 18,849 shares of the company’s stock valued at $211,000 after purchasing an additional 13,986 shares during the period. Virtus Investment Advisers LLC bought a new position in Oruka Therapeutics during the 4th quarter valued at approximately $267,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Oruka Therapeutics by 38.7% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 10,207 shares of the company’s stock worth $309,000 after buying an additional 2,849 shares during the period. Finally, Rhumbline Advisers purchased a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $320,000. Institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

ORKA has been the subject of a number of recent research reports. BTIG Research boosted their target price on Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Wedbush boosted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.50.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.